GlassScriptPhysician profile
Beth Leanne Brogan
NPI 1700892809
$2,330.74
in general payments reported to CMS, 2019-2025
20 companies · $1,131 in 2025
The $1,131 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.98 · 2023: $155 · 2024: $996 · 2025: $1,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,107 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,107.18 |
| Education | $175.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $733.24 | 2023-2025 | Blu-U, Odomzo, Absorica Ld |
| Amgen INC. | $266.38 | 2023-2025 | Otezla, Otezla |
| Abbvie INC. | $220.54 | 2023-2025 | Skyrizi |
| Novartis Pharmaceuticals Corporation | $177.17 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $164.34 | 2024-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $113.70 | 2025 | Nemluvio |
| Janssen Biotech, INC. | $110.35 | 2019-2025 | Tremfya |
| Ucb, INC. | $110.04 | 2019-2025 | Bimzelx |
| Pfizer INC. | $106.50 | 2023-2025 | |
| Incyte Corporation | $79.15 | 2024 | Opzelura |
| Leo Pharma INC. | $76.26 | 2024-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $43.31 | 2024-2025 | Sotyktu |
| Genentech USA, INC. | $19.40 | 2024 | Erivedge |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.02 | 2024 | Spevigo |
| Integra Lifesciences Corporation | $17.06 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $16.09 | 2025 | Affinity |
| Verrica Pharmaceuticals INC. | $15.97 | 2024 | Ycanth |
| Mallinckrodt Hospital Products INC. | $15.39 | 2024 | Acthar |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.43 | 2019 | |
| Kerecis Limited | $12.40 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Brogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.